Gland Pharma (NSE:GLAND) Momentum Rank: 3 (As of Sep. 21, 2026) — 50% Below Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:GLAND Gland Pharma Ltd NSE:GLAND
81 GF Score
Price ₹2,940.20
GF Value ₹2,270.46
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Gland Pharma Momentum Rank?

Gland Pharma NSE:GLAND +1.86% 81 Momentum Rank is 3 as of Sep. 21, 2026, which is 50% below its 10-year median of 6.00. GuruFocus rates NSE:GLAND with a GF Score™ of 81/100 and a GF Value™ of ₹2,270.46 (Modestly Overvalued). The stock has 6 warning signs investors should review.

Gland Pharma has the Momentum Rank of 3.

Momentum Rank measures the strength and persistence of a stock's price movement over time, rated on a scale of 1 to 10.

For Momentum Rank, we considered the residual momentum concept that was widely studied by Blitz and his colleagues as well as by Nobel Prize laureates Fama and French. However, we did not find any significant differences in the performances of stocks with different ranks of residual momentum. Therefore, we use traditional momentum instead.

Momentum Rank is determined using the standardized momentum ratio and other momentum indicators. The standardized momentum ratio is the average of the performances from 12 months ago to 1 month ago and 6 months ago to 1 month ago, divided by the beta of the stock over the past 12 months. To calculate the momentum ratio today, we would use the average of the two performance numbers.

For momentum, we found that stock price performance does not have a monotonic correlation with the momentum ratio. The stocks with the highest momentum ratios perform worse than those at about the 70th percentile. Therefore, for the momentum rank, we ranked the stocks at about the 70th percentile of the momentum ratio as the highest at 10.

A higher score reflects strong price momentum and indicates greater potential for superior performance. Conversely, a lower score indicates that momentum is either too high or too low, and stocks tend to underperform.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Gland Pharma Momentum Rank Related Terms

NSE:GLAND vs ZTS: Momentum Rank Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Gland Pharma's Momentum Rank, along with its competitors' market caps and Momentum Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Gland Pharma Momentum Rank vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Gland Pharma's Momentum Rank distribution charts can be found below:

* The bar in red indicates where Gland Pharma's Momentum Rank falls into.


NSE:GLAND
81GF Score
Gland Pharma Ltd NSE:GLAND
Momentum Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Momentum Rank →
What does a Momentum Rank of 3 mean?
Gland Pharma (NSE:GLAND) has a Momentum Rank of 3 as of Sep. 21, 2026. Momentum Rank is determined using the standardized momentum ratio, measuring the speed and velocity of price changes in a stock. View historical data on Gland Pharma and its competitors. This is 50% below median its historical median of 6.00. Over the past decade, Gland Pharma's Momentum Rank has ranged from 1.00 to 10.00.
Is Gland Pharma's Momentum Rank too high?
Gland Pharma's current Momentum Rank of 3 is 50% below median its 10-year median of 6.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 10.00. Overall, Gland Pharma has a GF Score™ of 81/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Gland Pharma's Momentum Rank compare to ZTS?
Gland Pharma's Momentum Rank of 3 can be compared against companies in the Drug Manufacturers industry. Historically, Gland Pharma's own Momentum Rank has ranged from 1.00 to 10.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Momentum Rank for a Drug Manufacturers company?
A good Momentum Rank depends on the Drug Manufacturers industry context. However, Momentum Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Momentum Rank mean?
A high Momentum Rank can signal that a stock is expensive relative to its fundamentals. Momentum Rank is determined using the standardized momentum ratio, measuring the speed and velocity of price changes in a stock. View historical data on Gland Pharma and its competitors. Gland Pharma's current Momentum Rank is 3, which is 50% below median its own 10-year median of 6.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gland Pharma stock overvalued right now?
Based on GuruFocus' analysis, Gland Pharma (NSE:GLAND) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹2,270.46, compared to a current price of ₹2,940.20 — trading 29.5% above its estimated fair value. The current Momentum Rank is 3, which is 50% below median its 10-year median of 6.00. Gland Pharma's overall GF Score™ is 81/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Momentum Rank calculated?
Momentum Rank is calculated from a company's financial statements. For Gland Pharma (NSE:GLAND), the current Momentum Rank is 3 as of Sep. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Gland Pharma (NSE:GLAND) Overvalued in 2026?

Based on GuruFocus' analysis, Gland Pharma stock appears to be overvalued. The current stock price of ₹2,940.20 is trading 29.5% above its estimated GF Value™ of ₹2,270.46. GuruFocus considers Gland Pharma to be Modestly Overvalued.

Key valuation signals for NSE:GLAND:

  • Momentum Rank: 3 (50% below median its 10-year median of 6.00)
  • GF Value™: ₹2,270.46 vs. price of ₹2,940.20 (29.5% above fair value)
  • GF Score™: 81/100 with 6 warning signs

No single metric tells the full story. See the NSE:GLAND stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Gland Pharma Business Description

Other Exchanges 543245:India
Address TSIIC, Phase - IV, Plot No. 11 and 84, Pashamylaram (V), Patancheru M, Sangareddy District, Hyderabad, TG, IND, 502307
Gland Pharma Ltd is engaged in the development, manufacturing, and marketing of complex injectables. The company's key molecules include Heparin Sodium Injection, Enoxaparin Sodium Injection, Rocuronium Bromide Injection, and Daptomycin Injection, among others. The group is also involved in a vast range of therapeutic categories, including Anti-Infectives, Anesthetics, Anti-Coagulants and their Antidotes, Anti-Malarials, Cardiology, and more, to Hormones and related Drugs, Fertility Supplements, and GnRH Agonists and Antagonists. Geographically, it derives a majority of revenue from the USA, and the rest from Europe, India, Canada, Australia, and other regions.
81GF Score

Get the complete analysis for NSE:GLAND

Momentum Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹2,940.20
Price
₹2,270.46
GF Value